In this report, the effects of a combined treatment with the proteasome inhibitor bortezomib and either a recombinant adenoassociated virus type 2 (rAAV-2)-mediated p53 gene transfer or chemotherapeutic agents, docetaxel and pemetrexed, were tested on p53 positive and p53negative non-small cell lung cancer (NSCLC) cell lines. The combination of bortezomib and rAAV-p53 led to a significant synergistic inhibition of cell growth between 62-82% depending on the p53 status of the cell line and drug concentration. Surviving cells of the combined treatment showed a significant reduced ability to form colonies. Enhanced cell toxicity was associated with a 5.3-14.4-fold increase of the apoptotic rate and intracellular p53 level up to 50.4% following vectormediated p53 restoration and bortezomib treatment. In contrast, an antagonistic effect on tumor cell growth and colony formation was observed for the combination of bortezomib and docetaxel or pemetrexed as a reduction of cell growth between 31 and 48% was found in comparison to 50% using the single agents. Lower cytotoxic effects were associated with significantly reduced apoptosis and an increase of clonogenic growth. The observed antagonistic effects between bortezomib and docetaxel or pemetrexed might influence clinical trials using these compounds. Conversely, p53 restoration and bortezomib treatment led to enhanced, synergistic tumor cell toxicity.
Introduction
Non-small cell lung cancer (NSCLC) represents the majority of lung cancers and is incurable in advanced stages. This is reflected by a 5-year survival rate of less than 3% and a median survival of 8-11 months after a standard chemotherapy. 1, 2 Considering the poor prognosis, second-line therapies for patients with progressive disease have been approved, such as docetaxel and pemetrexed. 3, 4 In a phase III trial, both administered as single agents showed comparable median survival of 7.9-8.3 months and a 1-year survival of 30% for docetaxel and pemetrexed, respectively. 5 Gene therapy is a possible modality for the treatment of patients with lung cancer. As p53 is lost or mutated in numerous cancers, a number of trials used viral vectors to restore wild-type p53. 6, 7 Unfortunately, gene therapy strategies restoring p53 alone or in combination with chemotherapy failed to improve the outcome of the patients. 8 A new class of biologically active agents in lung cancers are proteasome inhibitors. Bortezomib is a dipeptide boronic acid and a potent, highly selective and reversible inhibitor of the 26S proteasome. 9 Next to lung cancer, in vitro and in vivo studies have shown antitumor activity as a single agent in a wide range of solid and hematological malignancies, including prostate, breast, colon, pancreatic cancers and myeloma. 10, 11 Consequently, it was approved in 2003 for the treatment of advanced multiple myeloma. The 26S proteasome plays a critical role in the degradation of proteins involved in multiple cellular processes, including the cell cycle, transcription-factor activation, apoptosis and intracellular signal-transduction traffic, which are relevant for tumor progression and drug resistance. 12 The proteasome degrades the tumor suppressor p53, which is required for the transcription of a number of genes involved in cell-cycle control and DNA synthesis. 13 Wild-type p53 is stabilized by proteasome inhibition in cancer cell lines, 14, 15 suggesting a mechanism of bortezomib-induced apoptosis that may be relevant in suppressing cancer progression. 16, 17 We focussed on bortezomib as a promising agent to investigate if its combination with p53 gene transfer might enhance cytotoxicity in NSCLC cell lines. Further, the two chemotherapeutic drugs, pemetrexed (Alimta) and docetaxel (Taxotere), were used in combination with bortezomib to analyze the effects on NSCLC cell lines.
Our preclinical findings describe drug interactions between bortezomib, p53 and cytotoxic agents, which might influence further clinical studies that are currently planned for patients with recurrent NSCLC.
Material and methods

Cell culture
The NSCLC cell lines H460 showing wild-type p53 expression 18 and the p53-negative cell line H1299, in which both copies of the p53 gene are deleted, 19 as well as T47D cells (ductal carcinoma of the breast) with mutant p53 were cultured in Rosewell Park Memorial Institute (RPMI)-1640 medium (Sigma, Deissenhofen, Germany) supplemented with 10% heat-inactivated fetal calf serum (PAA Laboratories, Linz, Austria), 2 mM L-glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin (all Sigma). All cell lines were cultured in a humidified atmosphere with 5% CO 2 at 371C. The H1299 and the H460 cells were highly susceptible for recombinant adenoassociated virus type 2 (rAAV-2)-mediated gene transfer with a mean transduction rate of 82%. 20 The human embryonic kidney cells 293T were cultured under the same conditions using Dulbecco's modified Eagle's medium (Sigma) instead of RPMI-1640.
Production of recombinant AAV-2 vector stocks
Recombinant AAV-2 vector stocks containing the p53 gene (AAV-2-p53) and the green fluorescent protein (GFP)-gene (AAV-2-GFP) were produced as described previously. 21 Briefly, 293T cells were cotransfected with 20 mg vector plasmid (pAAV-p53-AR6, 20 respectively, pAAV-GFP-AR6 22 ) and 20 mg helper plasmid (pDG 23 ) using calcium phosphate precipitation. Three days later, 293T cells were harvested and lysed by three freeze-thaw cycles following sonication. The lysate was centrifuged and the supernatant was subjected to an iodixanol gradient to purify viral particles. 24 After centrifugation, fractions of 500 ml were collected and dialysed against RPMI-1640 for 24 h at 41C. AAV-2-p53 and AAV-2-GFP fractions were quantified using a quantitative real-time PCR for titration of infectious particles as described previously. 25 Cell culture and treatment with drugs 5 Â 10 4 lung cancer cells were cultured in 24-well plates and incubated with different concentrations of bortezomib, rAAV-p53, docetaxel and pemetrexed, alone and in combination. After 3 days, cells were detached with trypsin/ethylenediaminetetraacetic acid (Sigma) and resuspended with RPMI medium in a final volume of 1000 ml. Viable cells were assessed as stated below.
To determine the concentration required for 50% inhibition of growth (inhibitory concentration 50%, IC 50 ) for rAAV-p53, cells were incubated with rAAVp53 in different multiplicities of infections (MOIs) between 10 and 1000. For bortezomib, pemetrexed and docetaxel experiments, dose-response curves for each drug were determined by incubating the cells with dilutions between 0.0001 and 100 mM of the drug. For further experiments, the IC 50 of rAAV-p53, pemetrexed and docetaxel was chosen for combination with the IC 50 and IC 25 of bortezomib. These concentrations were considered as suitable to analyze growth inhibitory effects on the lung cancer cell lines.
In an attempt to evaluate subadditive, additive or overadditive growth inhibitory effects of bortezomib, rAAV-p53, pemetrexed and docetaxel on NSCLC cell lines, we calculated hypothetical combined survival rates by multiplying the effects of each drug given as a single agent. The calculated survival rates were compared with the measured survival rates of the combined treatment.
Assessment of viable cells
The viability of cells was assessed by Trypan blue exclusion and by counting using a Neubauer counting chamber. The survival rate in percent was calculated by dividing the number of viable cells by the number of viable untreated control cells multiplied by 100. Inhibition in percent was calculated by the following formula: inhibition in % ¼ 100%Àsurvival rate in %.
Clonogenic assay
Clonogenic assays were performed with surviving cells following treatment with bortezomib, rAAV-p53, docetaxel or pemetrexed as described above. After incubation of the cells with different drugs in different concentrations (IC 25 and IC 50 ) for 3 days, 5 Â 10 2 viable cells were assessed by Trypan blue exclusion and placed in 25 cm 2 flasks with fresh medium. After 7 days, colonies were counted using a light microscope. Only colonies containing more than 50 cells were counted. The percentage of colonies was calculated by dividing the number of colonies derived from treated cells by those from untreated cells and multiplying by 100.
Apoptosis assay
To determine and quantify the induction of apoptosis, DNA fragmentation was measured using a cell death detection enzyme-linked immunosorbent assay (ELISA) kit (Roche, Molecular Biochemicals, Mannheim, Germany). The enrichment of mono-and oligonucleosomes in the cytoplasm of apoptotic cells is attributable to the fact that DNA degradation occurs several hours before plasma membrane breakdown. After treatment of the cells as described above, 1 Â 10 4 cells were used for the ELISA procedure, according to the manufacturer's protocol. DNA fragmentation was quantified at 405 nm in a 1420 Multilabel Counter (EG&G Wallac, Turku, Finland). The enrichment of mono-and oligonucleosomes released into the cytoplasm was calculated as absorbance of sample cells/absorbance of untreated control, whereas the measured apoptosis rate from the untreated cells was defined as 1.
Western blot analysis
Western blot was performed as already described. 20 Briefly, 1 Â 10 5 cells were plated in 24-well plates and incubated with an IC 50 of rAAV-p53 and bortezomib alone and in combination with bortezomib for 24 h. As primary antibodies, a monoclonal mouse antihuman p53 antibody (Clone DO-7, Dako Cytomation, Hamburg, Germany; dilution 1:500) and a monoclonal mouse antirabbit glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (Clone 6C5, Acris Antibodies, Hiddenhausen, Germany; dilution 1:25000) were used. The primary antibodies were detected with a peroxidasecoupled rabbit antimouse secondary antibody (P0161, Dako Cytomation, Hamburg, Germany; dilution 1:1000). Immuncomplexes were visualized with an enhanced chemiluminescence kit (Amersham, Buckinghamshire, England) according to the manfacturer's instructions.
As a positive control, T47D cells, which express p53 at high levels, were used. T47D p53 has a point mutation in codon 194 that leads to stabilization and accumulation of nonfunctional p53 protein. 26 To compare the different bands, an AlphaImager Imaging System (Biozym Scientific GmbH, Oldendorf, Germany) and AlphaEase FC software (Biozym Scientific GmbH) were used. To determine relative changes in the p53 expression, the value of the p53 band was divided by the value of the corresponding GAPDH control band and multiplied with 100.
Statistical analysis
All assays were performed in triplicate and repeated at least for three times. The mean results of the nine independent experiments and the s.d. are presented in the text. For statistical analysis, the two-sided Student's t-test was used. Statistical significance was defined as Po0.05.
Results
Effects of bortezomib, rAAV-p53, docetaxel and pemetrexed as single agents on NSCLC cell lines First, we investigated the cytotoxic effects of bortezomib, rAAV-p53, docetaxel and pemetrexed on the NSCLC cell lines H1299 and H460 after a 3-day incubation period of each single agent using concentrations ranging between 0.0001 and 100 mM for the chemotherapeutics and between a MOI of 10 and 1000 for rAAV-p53. The three drugs led to a dose-dependent growth inhibition in both cell lines ( Figure 1 ). According to these data, we evaluated the IC 50 for each agent and the IC 25 for bortezomib. A concentration of 0.03 mM bortezomib led to a 25% and 0.05 mM to a 50% growth inhibition in both cell lines. The IC 50 for pemetrexed was 0.1 mM for both cell lines. For docetaxel, the IC 50 was 0.01 mM for the H1299 cells and 0.005 mM for the H460 cells. The rAAV-p53 vector led to a 50% growth inhibition of the H1299 and H460 cells at a MOI of 150 and 400, respectively. The IC 50 of each drug and the IC 25 of bortezomib were used for the following experiments.
Effects of bortezomib combined with rAAV-2-mediated p53 gene transfer Having evaluated the effects of the single agents on NSCLC cells, we asked next whether a coincubation of bortezomib and rAAV-p53 might lead to a pronounced growth inhibition. Therefore, cell lines were incubated with an IC 25 and IC 50 of bortezomib and an IC 50 of rAAV-p53. After a 3-days incubation period, an additive effect of p53 and bortezomib was observed in a dose-dependent manner (Figure 2a and b) . When cells were treated with bortezomib at an IC 25 Effects of bortezomib, p53 and chemotherapy on NSCLC cells J Neukirchen et al respectively, in comparison with untreated cells. Using an IC 50 for bortezomib, the growth reduction was 74% (s.d.72.4%) in the p53-negative cell line H1299. Comparing the reduction of viable cells with the calculated survival rates of the combined treatment, an additive effect was found for H1299 cells with a growth reduction of 74%, which was almost identical to the calculated value of 75% using the IC 50 . In the p53 positive cell line H460, the additive growth inhibitory effect of the combined treatment was more evident. This is reflected by a growth inhibition of 84% (s.d.74.0%) using an IC 50 for bortezomib, significantly exceeding the calculated growth inhibition of 75% (Po0.002). In contrast to rAAV-p53, no growth inhibition was observed for the control vector rAAV-GFP.
Following combined bortezomib and rAAV-p53 treatment, a fraction of the tumor cells survived. Therefore, we were interested in the ability of those surviving tumor cells to form colonies. We found that bortezomib and rAAVp53 treated cells were significantly inhibited in their ability to form colonies in comparison to cells that were treated with bortezomib-and the control vector rAAV-GFP (Figure 2c ). In particular, the combined treatment with bortezomib and rAAV-p53-led to a significant colony reduction of 55% (s.d.74.0%) and 58% (s.d.73.4%) when IC 25 and IC 50 were used in H1299 cells (Po0.001). The inhibitory effect on clonogenic colony growth for the p53-positive cell line H460 was more distinct. The combined treatment with IC 25 and IC 50 led to a significant reduction of the colony growth p53 expression after rAAV-2-mediated p53 gene transfer and bortezomib treatment The expression of p53 in H1299 (p53-null) and H460 (WT p53) cells after treatment with bortezomib and rAAV-p53 alone and in combination was examined by immunoblotting ( Figure 3 ). Owing to the homozygous deletion of the p53 gene, the p53-null H1299 cells did not express p53 after treatment with bortezomib. After infection of the cells with rAAV-p53 using an MOI of 150 infectious particles per cell, restoration of p53 expression was detected. The combined treatment with bortezomib and rAAV-p53 led to an increase of p53 expression of 29.3% in comparison to the single treatment with rAAV-p53. The WT p53 positive H460 cells exhibit a low p53 expression. After treatment with either bortezomib or rAAV-p53, an increase of 7.4 and 32.7% of p53 level was observed, respectively, indicating successful inhibition of p53 degradation and restoration. The combined treatment of bortezomib and rAAV-p53 led to the strongest intracellular increase of p53 of 50.4% in comparison with untreated cells.
Apoptotic activity following p53 and bortezomib treatment in NSCLC cell lines
In an attempt to ascertain if the synergistic effects of bortezomib and rAAV-2-mediated p53 gene transfer are associated with an increased apoptosis rate in the NSCLC cell lines, apoptotic activity following various treatments were determined by relative changes of DNA fragmentation of treated cells in comparison to untreated cells (Figure 4) . A significant dose-dependent increase of apoptotic activity was seen in both cell lines using a combination of rAAV-p53 and bortezomib in comparison to untreated cells. In particular, for H1299 cells a significant increase of apoptosis ranging from a factor of 3.9 (s.d.70.9) to 5.3 (s.d.70.6) was seen when cells were treated with bortezomib with an IC 25 and IC 50 in combination with rAAV-p53, respectively (Po0.001). In the H460 cells, a significant dose-dependent increase of the apoptotic activity of the factor 9.2 (s.d.71.9) and 14.5 (s.d.72.4) was observed when using rAAV-p53 and bortezomib at an IC 25 and IC 50 , respectively (Po0.001). In contrast, this effect was not seen when cells were treated with the control vector rAAV-GFP.
Effects of the combined treatment of bortezomib and the cytotoxic chemotherapeutic agents docetaxel and pemetrexed Next, the effects of a combination of the cytotoxic agents docetaxel or pemetrexed with bortezomib on NSCLC cell 25 and an IC 50 in combination with pemetrexed, a growth inhibition of 31% (s.d.74.3%) and 41% (s.d.74.3%) was observed. As a result, the addition of either docetaxel or pemetrexed to bortezomib led to a significantly antagonistic effect with regard to growth inhibition in both cell lines ( Figure 5a) .
Next, we asked if the surviving cells of the combined treatment were able to form more colonies than the cells treated with one drug alone in a clonogenic assay. As a result, the cells of the combined treatment had the same or higher ability for clonogenic growth in comparison to cells just treated with one agent (Figure 5b ). This is exemplified at its best when looking at pemetrexed as a single agent. Colonies were reduced by 44 (s.d.79.8%) and 47% (s.d.76.2%) for H1299 and H460, compared to untreated cells. In contrast, the combination of pemetrexed and bortezomib led to an increase of clonogenic growth. The reduction of colonies compared to untreated cells was between 30% (v8.4%) and 42% (s.d.75.0%) depending on the cell type and IC of bortezomib. The reduction of the antiproliferative efficacy of the combined treatment in comparison with the single agent pemetrexed was statistically significant for both concentrations and both cell lines (Po0.05).
Apoptotic activity of bortezomib in combination with the chemotherapeutic agents To find out if the antagonistic effects of bortezomib and the cytotoxic agents were associated with decreased apoptosis, the apoptotic activities for the different treatments were determined. Docetaxel as a single agent increased the apoptotic activity in H1299 and H460 cells by the factor 3. The apoptotic activity was significantly lower when the combination of docetaxel and bortezomib was used (Po0.05). Depending on the cell line and concentration of bortezomib, the apoptotic activity was increased between a factor of 1.9 and 4.2.
Using pemetrexed as a single agent, the apoptotic activity was 2.5 (s.d.71.0) and 2.9 (s.d.70.4) fold increased for H1299 and H460 compared to untreated control, respectively. Similar to previous results, the combination of pemetrexed and bortezomib led to a significantly decreased apoptotic activity between a factor of 1.4 and 2.7 for the different cell types and concentrations (Figure 6 ; Po0.05).
Discussion
In this study, we were interested in the growth inhibitory and proapoptotic effects of the proteasome inhibitor bortezomib on NSCLC cell lines in the presence or Effects of bortezomib, p53 and chemotherapy on NSCLC cells J Neukirchen et al absence of p53. We found that bortezomib inhibits tumor cell growth in p53-negative and p53-positive NSCLC cell lines, suggesting p53-independent effects. After rAAV-2-mediated p53 restoration in p53-negative cells, significant additive effects on growth inhibition in different assays and an increased induction of apoptosis were observed. The inhibition of p53 degradation by the proteasome inhibition was reflected by an increased intracellular p53 concentration as assessed in Western blot analysis. Interestingly, looking at the p53-positive NSCLC cell line, the synergistic effects between p53 gene transfer and bortezomib were even more distinct. Enhancement of p53 concentrations in p53 positive or negative tumor cells and the treatment with bortezomib led to significant overadditive effects with regard to inhibition of tumor cell growth and induction of apoptosis. This effect possibly results from the intracellular increase of p53 and a lack of p53 degradation caused by the treatment with bortezomib. These results are in line with the finding that p53 rapidly accumulates in cells treated with proteasome inhibitors 9, 27 and underline the observation of p53-mediated sensitization for proteasome inhibitor-induced apoptosis.
16 p53 gene transfer was chosen for combination with bortezomib for several reasons. First, p53 plays an essential intracellular role with regard to cell cycle regulation, DNA repair and apoptosis. 28 Second, mutations in the p53 gene are frequently observed in up to 60% of all NSCLC, 29 playing a critical role in tumor formation, progression and chemoresistance, thus leading to an inferior prognosis for the patient. 30, 31 Third, p53 associated apoptosis is regulated by proteasome degradation. 17 For p53 gene transfer, an rAAV-2 vector was used as we previously demonstrated that NSCLC cells are highly susceptible for rAAV-2. 20, 32 The results of previous clinical trials using p53 gene replacement therapy in combination with chemotherapy were disappointing. Although the approach was safe and restoration of p53 was successful, the clinical benefit for the patient was marginal. 7, [33] [34] [35] Here we were able to demonstrate a synergism between p53 restoration and a new class of cancer drugs, the proteasome inhibitors. The overadditive effects of bortezomib and p53 gene transfer might be relevant for clinical trials based on tumor suppressor gene replacement. The combination with bortezomib seems to be beneficial with regard to the inhibition of p53 degradation in p53-positive and p53-negative NSCLCs.
We next looked at the biological effects of the proteasome inhibitor bortezomib and the cytotoxic agents pemetrexed and docetaxel. Preliminary experimental data have demonstrated that bortezomib is able to sensitize cancer cell lines to chemotherapeutics such as doxorubicin or melphalan as seen for patients with multiple myeloma. 12, 27 Others found sequential effects with regard to the time of administration using gemcitabine and carboplatin in combination with bortezomib. 14 We chose docetaxel and bortezomib as these two agents have shown to improve survival and life quality of patients with NSCLC as single agents in the second-line therapy. In contrast to p53 gene transfer, no synergism was found for the combination between bortezomib and the cytotoxic drugs. The simultaneous treatment of NSCLC cells with bortezomib and docetaxel as well as with pemetrexed did not lead to an enhanced inhibition of cell growth. Moreover, we found a significant reduction of growth inhibition and reduced apoptosis for the combination of bortezomib and chemotherapy, suggesting an antagonism between the drugs. Our results are consistent with the observations by others, demonstrating that bortezomib failed to enhance docetaxel-induced apoptosis in human pancreatic tumor xenografts. 36 Although the antitumoral effects of pemetrexed are well studied in a variety of clinical investigations, 37 there are no data about the effects of pemetrexed in combination with proteasome inhibition in NSCLCs. Pemetrexed, as a multitargeted antifolate, causes an arrest in the S phase of the cell cycle. 38 Docetaxel is lethal towards cells in S phase by affecting centrosome organization 39 whereas bortezomib causes a G 2 /M-phase arrest. 40 Consequently, when bortezomib and a chemotherapeutic drug are administered simultaneously, the bortezomib-mediated G 2 /M arrest prevents cells from entering the part of the cell cycle in which the chemotherapeutical agents develop their definitive lethal activity as observed by Nawrocki et al.
36
Based on the data of our in vitro studies, the design of clinical trials using bortezomib and cytotoxic drugs in combination might be without improvement for the patients. Although the antagonistic effects of bortezomib in combination with chemotherapeutical agents have not been studied in xenograft models, there is evidence that our results are of relevance in the clinical setting. This is exemplified by a clinical phase II study for patients with advanced NSCLC published at the ASCO in 2005. Fanucchi et al. 41 treated 155 patients with advanced NSCLC with bortezomib alone and in combination with Figure 6 Apoptotic activity in NSCLC cell lines H1299 (black bars) and H460 (white bars) measured by DNA fragmentation after combined treatment with bortezomib and cytotoxic agents docetaxel or pemetrexed. A significantly decreased apoptotic activity was seen for the combined treatment in comparison to the single agent (Po0.05).
Effects of bortezomib, p53 and chemotherapy on NSCLC cells J Neukirchen et al docetaxel. Bortezomib plus docetaxel was generally well tolerated with manageable toxicities but no advantage for the patients' outcome in terms of overall-response rate and survival was observed compared to bortezomib monotherapy. Consequently, a combination of docetaxel or pemetrexed with bortezomib should be reconsidered in further clinical trials.
